IP Library Granted Patent US 9,770,438
Granted Patent B2
US 9,770,438 · App. 14/852,039 · Granted Sep 26, 2017

Clonidine formulation in a polyorthoester carrier

Inventors: Christopher M. Hobot (Tonka Bay, MN); Phillip E. McDonald (Plymouth, MN); Keith R. Hildebrand (Houlton, WI)
Assignee: Warsaw Orthopedic, Inc.
A61K31/4168A61K9/0019A61K9/0024A61K9/0085A61K9/1647A61K31/415A61K47/34A61K9/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,770,438
App. No.
14/852,039
Granted
Sep 26, 2017
Kind
B2
Abstract

Effective treatments of acute pain for extended periods of time are provided. The treatments include the administration of one or more drug depots at or near a target site wherein the drug depots include an effective amount of clonidine formulated within a polyorthoester. By administration of one or more drug depots at or near the target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discongenic back pain and joint pain, as well as pain that is incidental to surgery. In some embodiments, the relief can be for at least twenty-five days, at least fifty days, at least one hundred days or at least one hundred and thirty-five days.

Claims (6)

1. A method for treating acute pain, wherein said method comprises implanting a drug depot in an organism to reduce or treat pain, wherein said drug depot comprises clonidine in an amount from about 0.1 wt. % to about 30 wt. % of the drug depot, and a polyorthoester, and the drug depot is a gel having an inherent viscosity of about 0.10 dL/g to about 1.2 dL/g, and the drug depot further comprises an excipient comprising mPEG in an amount from about 0.001 wt. % to about 2 wt. % of the drug depot.

2. A method according to claim 1 , wherein said clonidine comprises from about 5 wt. % to about 15 wt. % of the drug depot.

3. A method according to claim 1 , wherein said clonidine is capable of being released from the drug depot in an amount between 0.005 and 1.0 mg per day for a period of 5 to 135 days.

4. A method according to claim 1 , wherein the drug depot releases about 5% to about 100% of said clonidine relative to a total amount of said clonidine loaded in the drug depot over a period of 3 to 200 days after the drug depot is implanted in said organism.

5. A method according to claim 1 , wherein said polyorthoester comprises at least 70 wt. % of the drug depot.

6. A method according to claim 1 , wherein the drug depot has a modulus of elasticity of about 5×10 4 to about 5×10 5 dynes/cm 2 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 31, 2020
From: MEDTRONIC INC.
To: COMPANION SPINE, LLC
Reel/Frame 054787/0479 →
Continuity (4)
Division 12412024 · Mar 26, 2009
Provisional Application 61046213 · Apr 18, 2008
Provisional Application 61046201 · Apr 18, 2008
Related Publication 20150374665A1 · Dec 31, 2015